AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04797260 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene therapy
Description: Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
Study NCT06482008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib
Description: HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
Study NCT05936866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor stretching
Description: Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises , seated pelvic tilts, cat stretches, seated hip openers (2 sets, 8 reps, sustained for 6 seconds) Week 5 to 8: Pelvic floor muscles awareness, Breathing exercises ,seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog (2 sets, 8 reps, sustained for 6 seconds) Week 9 to 13: Pelvic floor muscles awareness, Breathing exercises, seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog side lying clamshells, mini squats with support (2 sets, 9 reps, sustained for 7 seconds)
Study NCT05936866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor strengthening
Description: Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises, 2 Sets of 10 Reps for pelvic floor squeeze and release Seated marching with elastic band with pelvic floor squeeze.~Week 5 to 8: 2 sets x 9 Reps for Pelvic floor squeeze and release, Seated marching with elastic band with pelvic. 2 Sets x 8 Reps for bridging with pelvic floor squeeze, side lying hip circles Week 9 to 13: 2 sets 10 reps for Pelvic floor squeeze-and-release, Seated marching with elastic band with pelvic floor squeeze, pelvic bridging with pelvic floor squeeze, side lying hip circles with pelvic floor squeeze. 2 sets, 8 reps for . side lying Clamshells with resistance band and pelvic floor squeeze and plie squats with pelvic floor squeeze
Study NCT05274490 — intervention group
Intervention type: PROCEDURE
Intervention: intubation and mechanical ventilation
Description: patients who were in need were intubated and mechanically ventilated
Study NCT04889742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: loco-regional hyperthermia
Description: loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
Study NCT05137873 — intervention group
Intervention type: OTHER
Intervention: Dunn-2 infant Sensory Profile (PS2-N)
Description: The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
Study NCT06496165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
Study NCT06496165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
Study NCT05246709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Description: Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site.
Study NCT05246709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transparent film dressing
Description: A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
Study NCT05246709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard transparent film dressing
Description: A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
Study NCT04921904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150mg dose administered orally twice daily every day
Study NCT04921904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8mg/kg iv every 2 weeks until evidence of disease
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC educational materials
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive (P)REHAB exercise program
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App-Based Intervention
Description: Use ExerciseRx app
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App-Based Intervention
Description: Use FitBit app
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App-Based Intervention
Description: Use FitBit app
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Activity Tracker
Description: Wear FitBit
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wearable Activity Tracker
Description: Wear FitBit
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06040762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04734301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal Electrical Stimulation (2 times/week)
Description: IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
Study NCT04734301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravaginal Electrical Stimulation (5 times/week)
Description: IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
Study NCT05209373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: 4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
Study NCT05209373 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Control Condition
Description: 4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
Study NCT05665803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pediatric rotary files
Description: Mechanical preparation of primary tooth canals with pediatric rotary files
Study NCT05665803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual flare files
Description: Mechanical preparation of primary tooth canals with manual flare files
Study NCT05505864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Action Process Approach (HAPA)
Description: Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
Study NCT06356051 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Description: cardiovascular evaluation
Study NCT05354271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
Study NCT06186778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: secondary colonoscopy
Description: After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
Study NCT06186778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional colonoscopy
Description: It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
Study NCT05766306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Blend
Description: Participants will be taking 1 sachet a day, 3 billion CFU.
Study NCT05766306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be taking 1 sachet a day.
Study NCT04149145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344+Niraparib
Description: The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
Study NCT04149145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344+Niraparib
Description: In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
Study NCT04861766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® L
Description: Injection in both NLFs
Study NCT04861766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Injection in both NLFs
Study NCT06238882 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
Study NCT04362228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-body exercise
Description: 10-week one-on-one, virtual, whole-body exercise class, 3x/week, focused on increasing respiratory rate through moderate-intensity aerobic exercises.
Study NCT06392854 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: 2 dose insulin infusion 4 hours
Study NCT06058624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran ACT for Chronic Pain (VACT-CP)
Description: Participants receive 7 online modules, provided as weekly sessions that feature Coach Anne as a virtual, animated treatment guide. All content is presented interactively, through text-based conversations with Coach Anne. Veterans will hear what Coach Anne says and respond to her using text-based dialogue options that will trigger different responses from Coach Anne as the conversation progresses, to allow the system to responsively interact in a personalized manner with the Veteran. Veterans will also be presented with videos (e.g., Veteran narratives, metaphors), in-module assessments (e.g., values assessments), and interactive opportunities for goal setting.
Study NCT06058624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Pain School
Description: Participants will receive 7 modules (15 to 20 minutes each) of content based on a common non-ACT based VA treatment option, Pain School. The adaptation used for this study, Online Pain School, will support Veterans' self-management of their chronic pain by providing informational videos on chronic pain and its health impacts, short behavioral exercises to help with pain management, and psychoeducation on different wellness techniques for their pain management toolbox.
Study NCT05354271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
Study NCT05252507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paint Night
Description: There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
Study NCT06484387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social interaction
Description: Participants are required to speak to one another. Participants are given various topics of conversation.
Study NCT06096857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roseomonas mucosa (RSM2015) and Cardamom seeds
Description: Freeze dried packet to be reconstituted in water
Study NCT06096857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sucrose)
Description: Freeze dried packet to be reconstituted in water
Study NCT05234281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interdisciplincary concentrated group rehabilitation
Description: All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living
Study NCT05113537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given Orally
Study NCT06421376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardonilizumab
Description: Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
Study NCT05113537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-PSMA-617
Description: Given IV
Study NCT06262724 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast auto-augmentation
Description: Single group assignment. All patients included were subjected to utilizing chest wall perforator flaps for breast reshaping.
Study NCT04854928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 gel, 3%
Description: A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study NCT04854928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study NCT04130165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched donor human milk
Description: Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
Study NCT06420921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech in noise comprehension test
Description: Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
Study NCT06420921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech in noise comprehension test
Description: Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
Study NCT06420921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Objective tests of perception of ambient sound cues in noise
Description: Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
Study NCT06420921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Objective tests of perception of ambient sound cues in noise
Description: Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
Study NCT06420921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subjective tests of perception of ambient sound cues in noise
Description: Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
Study NCT06420921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjective tests of perception of ambient sound cues in noise
Description: Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
Study NCT05578820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stimotimagene copolymerplasmid
Description: Gene therapy drug, Intratumoral administration
Study NCT05311930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg/d Hetrombopag
Description: After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
Study NCT05578820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Antiviral drug, Intravenous administration
Study NCT05711472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: birth ball exercise
Description: birth ball exercise used in childbirth
Study NCT05571397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Continuous Glucose Monitor
Study NCT05692726 — intervention group
Intervention type: OTHER
Intervention: Patients
Description: Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
Study NCT04843098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL117
Description: TL117 capsules orally once daily
Study NCT04843098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
Study NCT06510894 — intervention group
Intervention type: DRUG
Intervention: Sotagliflozin
Description: Sodium-glucose cotransporter-1/2 inhibitor